This clinical trial is focused on studying a skin condition called hidradenitis suppurativa, which is characterized by painful lumps under the skin, often in areas like the armpits or groin. The study is looking at patients with moderate to severe forms of this condition. The main goal is to evaluate the effectiveness and safety of different investigational drugs compared to a placebo. One of the investigational drugs being tested is called VAY736, which is also known by its active substance name, ianalumab. This drug is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein.

Participants in the study will receive either the investigational drug or a placebo. The study is designed to be “blinded,” meaning neither the participants nor the researchers know who is receiving the actual drug and who is receiving the placebo. This helps ensure that the results are not influenced by expectations. The study will last for a period of 16 weeks, during which the participants’ response to the treatment will be closely monitored. The primary focus is to see how many patients show a clinical response, which means an improvement in their condition, after the treatment period.

Throughout the study, the safety of the participants will be a top priority. This includes monitoring for any side effects or adverse events, as well as conducting regular physical examinations and checking vital signs. The study aims to provide valuable information on the potential benefits and risks of using VAY736 for treating moderate to severe hidradenitis suppurativa, which could lead to new treatment options for patients with this challenging condition.